- TRADE NAME: Firdapse (Catalyst Pharma Inc)
- INDICATIONS: indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
- CLASS: Potassium channel blocker
- HALF-LIFE: 1.8–2.5 hours
- FDA APPROVAL DATE: 11/28/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: no data on associated risk
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
